From Bench to IPO.
Pattern Recognition Beats Credentials.
We’ve spent 20+ years inside drug development, financings, and exits. We’ve seen what actually moves assets forward and what quietly kills them. Most founders and investors learn these lessons the expensive way. We built systems so you don’t have to. Results outrank resumes. Every time.
The Mission: Merit Over Pedigree
Biotech markets itself as a data-driven industry. In practice, it often rewards networks, narrative, and recycled credentials over measurable execution.
We believe durable value is created by disciplined capital allocation, rigorous scientific evaluation, and aligned incentives – not prestige.
BowTiedBiotech is built around one core idea: outcomes beat optics. The best theses should stand on data, probability, and process, regardless of who presents them.
For independent investors, that means access to institutional-grade diligence without needing institutional connections.For insiders, it means clear-eyed analysis that pressure-tests assumptions instead of reinforcing them.
Equal access to insight. Unequal results based on performance.
Feature Company
Current Deep Dive: Immix Biopharma (IMMX)
The Setup
Micro-cap oncology company targeting relapsed/refractory AL amyloidosis. Lead asset faces a defined but high-mortality niche population with limited durable options.
Binary clinical inflection ahead. Valuation sensitive to signal clarity.
The Bull Case
- Clear unmet need with regulatory flexibility
- Small, focused trials with faster data cycles
- Strategic value if organ response durability is real
- Market cap low relative to peak-sales scenarios
The Bear Case
- Surrogate endpoints may not translate to durable organ improvement
- Financing risk between catalysts
- Competitive landscape tightening Micro-cap biotech risk premium remains elevated
What We’re Watching
- Depth and durability of organ response
- Safety in fragile patient population
- Cash runway vs next major readout
- Management capital allocation discipline
Our Approach
Every featured company is analyzed through the same lens:
Mechanism and clinical probability
Capital structure and dilution risk
Scenario-weighted valuation
Incentive
alignment
Full probability-weighted models and deeper analysis are published in the newsletter.
Our Services
The Newsletter | Market Intelligence
High-signal biotech analysis for investors who want probability, not press releases.
What You Get:
- Deep Dives: Full thesis breakdowns with mechanism, capital structure, risk modeling, and scenario analysis.
- Market Structure: Weekly reads on biotech capital flows, sentiment shifts, and positioning.
- Catalyst Mapping: Where expectations are mispriced and where they are justified.
- Career Strategy: Tactical guidance for scientists moving into capital markets, operating roles, or company formation.
Built for independent investors who want institutional-grade diligence.
Respected by insiders who want unfiltered perspective.
The Podcast | The Pulse of Science
Bi-weekly breakdowns at the intersection of innovation and money.
We cover:
- Breaking clinical data and what actually matters
- Financing trends and capital allocation
- M&A signals and sector positioning
- Structural shifts in biotech
No hype. No access journalism. Just analysis designed for clarity and edge.
Dropping Wednesdays and Saturdays.
Consulting | Strategic Advisory
Selective, high-conviction advisory for founders and funds.
Over 20 years across drug development, capital formation, M&A, and IPO execution.
We advise on:
- Capital strategy and financing structure
- Development pathway optimization
- Deal negotiation and exit positioning
- Incentive alignment and governance
Engagements are limited and by request only.
Fit matters more than volume.
What You Said
Featured Intel
-
ADC Saturation: Is Oncology Becoming a...on March 4, 2026A crowded oncology gold rush - or the beginning of ADC saturation?
-
BIOTECH MARKET RESEARCH $RLAY | Ep. 948on March 2, 2026Relay Therapeutics
-
The Illusion of Movement | Ep. 947on March 1, 2026Why Biotech Stocks Aren’t Going Anywhere Without Real Liquidity
Your Common Questions
Answered
How do I purchase your services?
Email us at BowTiedBiotech@gmail.com. We are happy to answer clarifying questions via email or voice chat.
Remind us of your qualifications?
We bring over 30 years of experience developing drugs, financing biotech companies, and executing successful exits through M&A and NASDAQ IPOs.
We remain actively engaged in the industry, applying hard-earned pattern recognition to both markets and operating strategy. Just as importantly, we invest time in helping the next generation of founders translate promising science into fundable, executable companies.
Experience matters. Execution matters more.
What is the service offering menu and pricing?
We are now publishing 7x per week according to the following cadence:
- [PAID FEATURE] Mondays: Stock Analysis & Biotech Catalysts
- Tuesdays: Biotech hot topics (X-article)
- Wednesdays: Podcast
- [PAID FEATURE] Thursdays: Public & Private Biotech Markets
- Fridays: Your Weekly Biotech Fix
- Saturdays: Podcast
- [PAID FEATURE] Sundays: Biotech Strategic Topics
How do I pay?
We use Stripe for processing payments. Stripe accepts most major credit cards (VISA, MasterCard, Discover, JCB, American Express) as well as apple pay, google pay, and bank transfers.